文献速递临床试验与 GCP流行病学与生物统计

减少血管升压药暴露对老年危重血管扩张性低血压患者90天死亡率的影响:一项随机临床试验

Effect of Reduced Exposure to Vasopressors on 90-Day Mortality in Older Critically Ill Patients With Vasodilatory Hypotension: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

该多中心随机临床试验纳入65岁及以上血管扩张性低血压的ICU患者2600例,比较允许性低血压(MAP目标60-65 mmHg)指导的血管升压药治疗与常规治疗。

要点

  • 在老年血管扩张性低血压患者中,允许性低血压策略未显著降低90天死亡率。
  • 允许性低血压组血管升压药暴露时间及剂量均低于常规治疗组。
  • 严重不良事件发生率两组相似,最常见为急性肾衰竭和室上性心律失常。

核心结论

  • 在65岁及以上接受血管升压药治疗的血管扩张性低血压患者中,允许性低血压策略与常规治疗相比未显著降低90天死亡率。
  • 解释临床重要性时应考虑主要结局点估计值的置信区间。

研究设计与样本

  • 多中心、实用性随机临床试验,在英国65个ICU进行,2017年7月至2019年3月纳入2600例患者。
  • 患者按1:1随机分配至允许性低血压组(MAP目标60-65 mmHg,n=1291)或常规治疗组(n=1307)。
  • 主要临床结局为90天全因死亡率;排除拒绝或撤回同意者后,2463例(95%)纳入主要结局分析。

主要发现

  • 允许性低血压组血管升压药中位持续时间为33小时,常规组为38小时(中位数差-5.0小时,95%CI -7.8至-2.2)。
  • 去甲肾上腺素等效总剂量中位数允许性低血压组为17.7 mg,常规组为26.4 mg(中位数差-8.7 mg,95%CI -12.8至-4.6)。
  • 校正预设基线变量后,90天死亡率的比值比为0.82(95%CI 0.68-0.98)。
  • 严重不良事件允许性低血压组79例(6.2%),常规组75例(5.8%);最常见为急性肾衰竭(41例[3.2%] vs 33例[2.5%])和室上性心律失常(12例[0.9%] vs 13例[1.0%])。

临床怎么用

  • 对于65岁及以上血管扩张性低血压的ICU患者,采用MAP目标60-65 mmHg的允许性低血压策略可减少血管升压药暴露,但未显著改善90天死亡率。
  • 临床决策时需结合主要结局的置信区间及校正后效应估计综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Vasopressors are commonly administered to intensive care unit (ICU) patients to raise blood pressure. Balancing risks and benefits of vasopressors is a challenge, particularly in older patients. OBJECTIVE: To determine whether reducing exposure to vasopressors through permissive hypotension (mean arterial pressure [MAP] target, 60-65 mm Hg) reduces mortality at 90 days in ICU patients aged 65 years or older with vasodilatory hypotension. DESIGN, SETTING, AND PARTICIPANTS: A multicenter, pragmatic, randomized clinical trial was conducted in 65 ICUs in the United Kingdom and included 2600 randomized patients aged 65 years or older with vasodilatory hypotension (assessed by treating clinician). The study was conducted from July 2017 to March 2019, and follow-up was completed in August 2019. INTERVENTIONS: Patients were randomized 1:1 to vasopressors guided either by MAP target (60-65 mm Hg, permissive hypotension) (n = 1291) or according to usual care (at the discretion of treating clinicians) (n = 1307). MAIN OUTCOME AND MEASURES: The primary clinical outcome was all-cause mortality at 90 days. RESULTS: Of 2600 randomized patients, after removal of those who declined or had withdrawn consent, 2463 (95%) were included in the analysis of the primary outcome (mean [SD] age 75 years [7 years]; 1387 [57%] men). Patients randomized to the permissive hypotension group had lower exposure to vasopressors compared with those in the usual care group (median duration 33 hours vs 38 hours; difference in medians, -5.0; 95% CI, -7.8 to -2.2 hours; total dose in norepinephrine equivalents median, 17.7 mg vs 26.4 mg; difference in medians, -8.7 mg; 95% CI, -12.8 to -4.6 mg). At 90 days, 500 of 1221 (41.0%) in the permissive hypotension compared with 544 of 1242 (43.8%) in the usual care group had died (absolute risk difference, -2.85%; 95% CI, -6.75 to 1.05; P = .15) (unadjusted relative risk, 0.93; 95% CI, 0.85-1.03). When adjusted for prespecified baseline variables, the odds ratio for 90-day mortality was 0.82 (95% CI, 0.68 to 0.98). Serious adverse events were reported for 79 patients (6.2%) in the permissive care group and 75 patients (5.8%) in the usual care group. The most common serious adverse events were acute renal failure (41 [3.2%] vs 33 [2.5%]) and supraventricular cardiac arrhythmia (12 [0.9%] vs 13 [1.0%]). CONCLUSIONS AND RELEVANCE: Among patients 65 years or older receiving vasopressors for vasodilatory hypotension, permissive hypotension compared with usual care did not result in a statistically significant reduction in mortality at 90 days. However, the confidence interval around the point estimate for the primary outcome should be considered when interpreting the clinical importance of the study. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN10580502.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Lamontagne F, Richards-Belle A, Thomas K, et al. Effect of Reduced Exposure to Vasopressors on 90-Day Mortality in Older Critically Ill Patients With Vasodilatory Hypotension: A Randomized Clinical Trial. JAMA. 2020. PMID: 32049269. doi:10.1001/jama.2020.0930

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。